Interestingly, unlike single-agent treatment with anti-PD-1/PD-L1 or anti-CTLA-4 antibodies, both anti-CD40 and OX40 antibodies as single agents have demonstrated efficacy in Pan02 tumor-bearing mice, in both subcutaneous and orthotopical models [35,49,50]. Here, TNFRSF4 is linked to neoplasm.